TARDBP and proteostasis deficiencies: With this in mind, we propose IKK and N-terminal phosphorylation of TDP-43 as potential therapeutic targets in the treatment of TDP-43 proteinopathies that would allow reduction of toxicity, specifically, reducing the aggregation of TDP-43 or its prone protein in cellular cytoplasm, while preserving physiological nuclear TDP-43 expression levels.